Identification of benzofurano[3,2-d]pyrimidin-2-ones, a new series of HIV-1 nucleotide-competing reverse transcriptase inhibitors.

Screening of our sample collection led to the identification of a set of benzofurano[3,2-d]pyrimidine-2-one hits acting as nucleotide-competing HIV-1 reverse transcriptase inhibitiors (NcRTI). Significant improvement in antiviral potency was achieved when substituents were introduced at positions N1, C4, C7 and C8 on the benzofuranopyrimidone scaffold. The series was optimized from low micromolar enzymatic activity against HIV-1 RT and no antiviral activity to low nanomolar antiviral potency. Further profiling of inhibitor 30 showed promising overall in vitro properties and also demonstrated that its potency was maintained against viruses resistant to the other major classes of HIV-1 RT inhibitors.

[1]  P. Edwards,et al.  Managing the liabilities arising from structural alerts: a safe philosophy for medicinal chemists. , 2011, Current medicinal chemistry.

[2]  K. Luthman,et al.  Effect of molecular charge on intestinal epithelial drug transport: pH-dependent transport of cationic drugs. , 1999, The Journal of pharmacology and experimental therapeutics.

[3]  E. Balaraman,et al.  Mitsunobu and related reactions: advances and applications. , 2009, Chemical reviews.

[4]  T. Hawkins.  Understanding and managing the adverse effects of antiretroviral therapy. , 2010, Antiviral research.

[5]  T. Cihlar,et al.  Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. , 2010, Antiviral research.

[6]  M. Radi,et al.  HIV-1 RT Inhibitors with a Novel Mechanism of Action: NNRTIs that Compete with the Nucleotide Substrate , 2010, Viruses.

[7]  Norio Miyaura,et al.  Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds , 1995 .

[8]  M. G. Albuquerque,et al.  HIV-1 reverse transcriptase: a therapeutical target in the spotlight. , 2006, Current medicinal chemistry.

[9]  R. Paredes,et al.  Clinical management of HIV-1 resistance. , 2010, Antiviral research.

[10]  K. Hertogs,et al.  Indolopyridones Inhibit Human Immunodeficiency Virus Reverse Transcriptase with a Novel Mechanism of Action , 2006, Journal of Virology.

[11]  B. Brodie,et al.  The gastric secretion of drugs: a pH partition hypothesis. , 1957, The Journal of pharmacology and experimental therapeutics.

[12]  K. White,et al.  Visualizing the molecular interactions of a nucleotide analog, GS-9148, with HIV-1 reverse transcriptase-DNA complex. , 2010, Journal of molecular biology.

[13]  R. Hamatake,et al.  Novel Nonnucleoside Inhibitors That Select Nucleoside Inhibitor Resistance Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase , 2006, Antimicrobial Agents and Chemotherapy.

[14]  Luis Menéndez-Arias,et al.  Molecular basis of human immunodeficiency virus drug resistance: an update. , 2010, Antiviral research.

[15]  A. Basavapathruni,et al.  Reverse transcription of the HIV‐1 pandemic , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  S. Broder,et al.  The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. , 2010, Antiviral research.

[17]  S. L. Le Grice,et al.  Mutations M184V and Y115F in HIV-1 Reverse Transcriptase Discriminate against “Nucleotide-competing Reverse Transcriptase Inhibitors”* , 2008, Journal of Biological Chemistry.

[18]  Marie-Pierre de Béthune,et al.  Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). , 2010, Antiviral research.